These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. [Cellular restriction factors that inhibit human immunodeficiency virus replication: new strategies in antiretroviral therapy]. Moreno-Valencia Y; Alvarez-García LX; Vázquez-Pérez JA Rev Invest Clin; 2014; 66(4):359-68. PubMed ID: 25695302 [TBL] [Abstract][Full Text] [Related]
5. Relationship between human immunodeficiency type 1 infection and expression of human APOBEC3G and APOBEC3F. Ulenga NK; Sarr AD; Thakore-Meloni S; Sankalé JL; Eisen G; Kanki PJ J Infect Dis; 2008 Aug; 198(4):486-92. PubMed ID: 18598197 [TBL] [Abstract][Full Text] [Related]
6. The DNA deaminase activity of human APOBEC3G is required for Ty1, MusD, and human immunodeficiency virus type 1 restriction. Schumacher AJ; Haché G; Macduff DA; Brown WL; Harris RS J Virol; 2008 Mar; 82(6):2652-60. PubMed ID: 18184715 [TBL] [Abstract][Full Text] [Related]
7. APOBEC3G & HTLV-1: inhibition without deamination. Strebel K Retrovirology; 2005 May; 2():37. PubMed ID: 15921532 [TBL] [Abstract][Full Text] [Related]
8. A critical function of toll-like receptor-3 in the induction of anti-human immunodeficiency virus activities in macrophages. Zhou Y; Wang X; Liu M; Hu Q; Song L; Ye L; Zhou D; Ho W Immunology; 2010 Sep; 131(1):40-9. PubMed ID: 20636339 [TBL] [Abstract][Full Text] [Related]
9. Cytidine deaminases APOBEC3G and APOBEC3F interact with human immunodeficiency virus type 1 integrase and inhibit proviral DNA formation. Luo K; Wang T; Liu B; Tian C; Xiao Z; Kappes J; Yu XF J Virol; 2007 Jul; 81(13):7238-48. PubMed ID: 17428847 [TBL] [Abstract][Full Text] [Related]
10. New insights into the role of Vif in HIV-1 replication. Schröfelbauer B; Yu Q; Landau NR AIDS Rev; 2004; 6(1):34-9. PubMed ID: 15168739 [TBL] [Abstract][Full Text] [Related]
11. From restriction factors to restriction enzymes. Griffiths PD Rev Med Virol; 2004; 14(1):1-2. PubMed ID: 14716687 [No Abstract] [Full Text] [Related]
12. Viral RNA is required for the association of APOBEC3G with human immunodeficiency virus type 1 nucleoprotein complexes. Khan MA; Kao S; Miyagi E; Takeuchi H; Goila-Gaur R; Opi S; Gipson CL; Parslow TG; Ly H; Strebel K J Virol; 2005 May; 79(9):5870-4. PubMed ID: 15827203 [TBL] [Abstract][Full Text] [Related]
16. Apolipoprotein B mRNA-editing enzyme, catalytic polypeptide-like 3G: a possible role in the resistance to HIV of HIV-exposed seronegative individuals. Biasin M; Piacentini L; Lo Caputo S; Kanari Y; Magri G; Trabattoni D; Naddeo V; Lopalco L; Clivio A; Cesana E; Fasano F; Bergamaschi C; Mazzotta F; Miyazawa M; Clerici M J Infect Dis; 2007 Apr; 195(7):960-4. PubMed ID: 17330785 [TBL] [Abstract][Full Text] [Related]
17. Uracil DNA glycosylase is dispensable for human immunodeficiency virus type 1 replication and does not contribute to the antiviral effects of the cytidine deaminase Apobec3G. Kaiser SM; Emerman M J Virol; 2006 Jan; 80(2):875-82. PubMed ID: 16378989 [TBL] [Abstract][Full Text] [Related]
18. The viral infectivity factor (Vif) of HIV-1 unveiled. Rose KM; Marin M; Kozak SL; Kabat D Trends Mol Med; 2004 Jun; 10(6):291-7. PubMed ID: 15177194 [TBL] [Abstract][Full Text] [Related]
19. Complementary function of the two catalytic domains of APOBEC3G. Navarro F; Bollman B; Chen H; König R; Yu Q; Chiles K; Landau NR Virology; 2005 Mar; 333(2):374-86. PubMed ID: 15721369 [TBL] [Abstract][Full Text] [Related]
20. The interferon-induced expression of APOBEC3G in human blood-brain barrier exerts a potent intrinsic immunity to block HIV-1 entry to central nervous system. Argyris EG; Acheampong E; Wang F; Huang J; Chen K; Mukhtar M; Zhang H Virology; 2007 Oct; 367(2):440-51. PubMed ID: 17631933 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]